CKD is also a muscle disease. Chronic kidney disease damages the kidneys most visibly, but the second-most clinically important consequence is what it does to muscle: progressive loss of lean mass that worsens fatigue, falls, hospitalizations, and mortality.
That muscle loss is not "deconditioning" from feeling tired. It is a biological program. The uremic environment of CKD reprograms muscle protein turnover by raising myostatin, suppressing IGF-1, and turning on the ubiquitin-proteasome system that chews protein into amino acids faster than synthesis can replace it.
Myostatin and CKD quick stats
- Affected population: Roughly 850 million people worldwide have some form of CKD; 4-5 million depend on dialysis
- Muscle wasting prevalence in dialysis patients: Approximately 50-75% develop measurable sarcopenia or protein-energy wasting
- Typical myostatin elevation: 3-40 ng/mL in dialysis patients depending on assay, generally higher than healthy controls
- Effect of 9 weeks of endurance training: 50% decrease in vastus lateralis myostatin mRNA in hemodialysis patients
- Major myostatin-targeted CKD trial: AMG745/PINTA745 in 51 hemodialysis patients — did not meet primary endpoint
- Approved myostatin drug for CKD muscle wasting: None, as of May 2026
Key takeaways
- CKD muscle wasting is driven by a uremic mix of inflammation, oxidative stress, metabolic acidosis, angiotensin II, and glucocorticoid excess that all converge on myostatin upregulation.
- The pathway runs: myostatin → ActRIIB → Smad2/3 → atrogin-1 and MuRF1 → ubiquitin-tagged muscle protein → proteasomal destruction. Myostatin also suppresses the anabolic IGF-1/Akt arm at the same time.
- Exercise is the single most consistent intervention that lowers myostatin in CKD. Endurance training reduced muscle myostatin mRNA by about 50% in nine weeks in hemodialysis patients.
- PINTA745, the only Phase 2 myostatin antibody trial run specifically in CKD muscle wasting, missed its primary endpoint in 2014.
- Standard care today is correcting acidosis, treating inflammation, managing protein intake carefully, and pushing structured resistance and aerobic training — not a drug.
How CKD turns on the muscle-wasting program
Five drivers, all working together. The uremic environment of advanced CKD is not one bad signal. It is a stack of bad signals that converge on the same end point.
The drivers identified in nephrology reviews:
- Low physical activity, often imposed by fatigue, dialysis schedules, and reduced functional capacity
- Chronic or acute inflammation with elevated TNF-α, IL-6, and CRP
- Oxidative stress from impaired antioxidant defenses and accumulated uremic toxins
- Angiotensin II elevation from renin-angiotensin system activation
- Metabolic acidosis (low bicarbonate) which directly activates protein breakdown
- Glucocorticoid excess driven by stress and inflammation
Each of these has been shown to raise muscle myostatin expression independently. Stacked together in a CKD patient on dialysis, they create the catabolic storm that defines CKD-associated muscle wasting.
This is part of why pure protein supplementation has not solved CKD muscle wasting. The signaling environment is telling muscle to break down faster than dietary protein can be assembled into new tissue.
What myostatin actually does once it is up
The pathway is well mapped. Once myostatin is secreted by muscle and circulating in the blood, it binds to the activin receptor type IIB (ActRIIB) on the muscle cell surface.
ActRIIB binding triggers recruitment and phosphorylation of the type I receptor (ALK4 or ALK5), which phosphorylates the intracellular Smad2 and Smad3 transcription factors. Phosphorylated Smad2/3 partners with Smad4 and translocates to the nucleus, where it activates transcription of two key atrogene targets:
- Atrogin-1 (also called MAFbx or Fbxo32) — an E3 ubiquitin ligase that tags muscle proteins for proteasomal destruction
- MuRF1 (also called Trim63) — another E3 ligase specifically tagging myosin heavy chains and other contractile proteins
The tagged proteins are pulled into the 26S proteasome and reduced to amino acids. The muscle fiber shrinks.
Myostatin also suppresses the opposite arm of the balance. It blocks IGF-1/Akt/mTOR signaling, which is the dominant pathway driving muscle protein synthesis. The net effect is double: less synthesis, more breakdown.
For the broader receptor biology, see ActRIIB and the myostatin pathway and our myostatin protein explainer.
Why dialysis is the worst part of the spectrum
The treatment compounds the problem. Maintenance hemodialysis solves the uremia problem partially but introduces its own muscle-wasting drivers:
- Amino acid loss in the dialysate during each session (roughly 5-8 grams per treatment for hemodialysis)
- Repeated bouts of catabolic activation triggered by dialysis itself
- Time spent immobile during sessions — typically 12 to 15 hours per week
- Frequent inflammation from access points, intercurrent infections, and cardiovascular events
- Bone-mineral disorders that contribute to weakness
The result is that dialysis patients lose muscle faster than late-stage CKD patients not yet on dialysis, even though the kidney function itself is being supported.
Studies in vastus lateralis muscle biopsies of hemodialysis patients have shown myostatin mRNA levels markedly higher than healthy controls, alongside elevated atrogene expression. The biological signal is unambiguous, even if the absolute serum myostatin numbers vary widely between assays.
What the PINTA745 trial showed
The cleanest test the field has run. AMG 745 / PINTA-745 was a peptibody (peptide-Fc fusion) developed by Amgen and Atara Biotherapeutics that bound and neutralized myostatin. The Phase 2 trial enrolled 51 hemodialysis patients with protein-energy wasting and randomized them to PINTA-745 or placebo.
The primary endpoint was change in lean body mass at 12 weeks. The trial did not meet that endpoint at a statistically significant level when reported in 2014, and the program was discontinued for CKD-related wasting.
The disappointment was familiar. Several myostatin programs (bimagrumab in sarcopenia, ACE-031 in DMD, domagrozumab in Duchenne) have shown clean biomarker movement and modest mass changes without translating into a primary functional endpoint win. The mechanism behaves; the trials do not.
That does not mean the biology is wrong. It often means the population is heterogeneous, the inflammation is too strong to be overcome by single-target blockade, and the endpoints are noisy.
For the related antibody programs that did and did not succeed in adjacent indications, see anti-myostatin antibody and bimagrumab.
What exercise actually does in CKD
Exercise is the single most consistent intervention. Across multiple studies in CKD and dialysis populations, both endurance and resistance training have produced measurable drops in muscle myostatin expression and corresponding gains in lean mass and strength.
The cleanest data point: a 9-week endurance exercise program in hemodialysis patients produced approximately a 50% decrease in myostatin mRNA in the vastus lateralis muscle, alongside increased lean mass and decreased fat mass. The protocol involved moderate-intensity cycling during dialysis sessions, performed three times per week.
Resistance training produces a similar effect through different mechanisms. Heavy or moderate-heavy loading acutely raises myostatin transcription (a stress response), then chronically suppresses it over weeks as muscle adapts. Net result over 8-12 weeks is lower resting myostatin and higher follistatin.
Practical limitations matter. Many dialysis patients cannot exercise off-day because of fatigue, and on-day training has to fit around the session. Intradialytic cycling has emerged as a practical solution that nephrology programs are increasingly adopting.
For a broader view on training, see our resistance training and myostatin and exercises that lower myostatin coverage. For the aging-driven side of muscle loss, see myostatin and sarcopenia and myostatin and aging.
What patients with CKD can do today
The evidence base, in order of strength.
| Intervention | Evidence | Practical note |
|---|---|---|
| Correct metabolic acidosis | Strong: oral sodium bicarbonate improves muscle protein balance | Nephrologist-managed; target serum bicarb 22-26 mmol/L |
| Structured exercise (intradialytic cycling, resistance training) | Strong: lowers muscle myostatin, raises lean mass | Best when supervised; intradialytic protocols work |
| Protein intake balance | Moderate: too low worsens wasting, too high stresses kidneys | Usually 1.0-1.2 g/kg/day for dialysis, lower for non-dialysis CKD |
| Treat inflammation sources | Moderate: catheter infections, access dysfunction, periodontal disease | Each cleared inflammatory source helps muscle |
| Vitamin D repletion | Moderate: low 25(OH)D associates with wasting in CKD | Activated D analogs are nephrology-managed |
| Bicarbonate plus exercise combined | Moderate-emerging: synergistic | Both at once is better than either alone |
| Myostatin-blocking drugs | None approved | Not available outside trials |
Several of the above (especially the medical management items) are nephrologist-directed. The lifestyle interventions are largely patient-driven once a clinician has signed off.
For the population overlap with aging and frailty, see myostatin and sarcopenia. For the metabolic overlap with diabetes (which is the leading cause of CKD globally), see myostatin, insulin resistance, and type 2 diabetes.
What is being studied now
Several active angles in 2026:
- Antisense oligonucleotide approaches to knock down myostatin expression directly in muscle (different mechanism from antibodies)
- Activin-A-targeted approaches given the role of activin A elevation in CKD muscle wasting
- Renin-angiotensin system blockers (ACE inhibitors, ARBs) being evaluated for their muscle-protective effect independent of blood pressure
- Bicarbonate-and-exercise combination trials in pre-dialysis CKD to slow muscle loss before dialysis starts
- Reuse of bimagrumab data from obesity/GLP-1 programs to inform whether ActRIIA/B blockade could help dialysis patients with sarcopenic obesity
None of this has yet produced an approved drug for CKD-associated muscle wasting. The next two to three years will likely be informative as the GLP-1-driven obesity programs read out.
Sources
- Bataille and Chauveau, "Emerging role of myostatin and its inhibition in the setting of chronic kidney disease", Kidney International 2018
- Bataille and Chauveau, NDT 2021, "Myostatin and muscle atrophy during chronic kidney disease"
- PLOS ONE, "Relationship between Blood Myostatin Levels and Kidney Function: Shimane CoHRE Study"
- Cellular Physiology and Biochemistry, "Skeletal Muscle and Kidney Crosstalk in Chronic Kidney Disease"
- Amgen press release on PINTA745 Phase 2 results
- International Journal of Molecular Sciences, antisense myostatin in CKD
Frequently Asked Questions
Why does kidney disease cause muscle loss?
CKD creates a uremic environment that raises muscle myostatin, suppresses IGF-1, drives metabolic acidosis, and activates the ubiquitin-proteasome system. These signals collectively tell muscle to break down faster than it can rebuild, even if protein intake is adequate. Dialysis itself adds amino acid loss and immobilization. The result is sarcopenia-like wasting layered on top of the underlying kidney disease.
Can a myostatin inhibitor help dialysis patients?
The only Phase 2 trial in this setting (PINTA-745 / AMG 745 in 51 hemodialysis patients) missed its primary endpoint in 2014, and no myostatin-targeted drug is currently approved for CKD-related muscle wasting. The biology is real but no Phase 3 winner has emerged. The next data wave will likely come from bimagrumab and similar drugs being studied in adjacent indications.
What exercise is safe for dialysis patients?
Intradialytic cycling (during the dialysis session) is the best-studied modality and lowers muscle myostatin while raising lean mass. Light to moderate resistance training on non-dialysis days is also safe for most patients after clearance from a nephrologist. Always discuss exercise with the dialysis center and any cardiologist involved, because cardiovascular comorbidity is common.
Should CKD patients eat more protein to protect muscle?
It depends on the stage. Pre-dialysis CKD usually does better on a controlled protein intake (around 0.6-0.8 g/kg/day) to slow disease progression. Dialysis patients typically need more, around 1.0-1.2 g/kg/day, because they lose amino acids during treatment. The right amount is individualized by stage, body size, and labs, and should be set by a nephrology dietitian rather than by general gym advice.
Does sodium bicarbonate really help muscle in CKD?
Yes, in patients with metabolic acidosis. Oral bicarbonate correction is one of the few interventions with consistent evidence for improving muscle protein balance in pre-dialysis CKD. It works by reducing the acid-driven activation of the ubiquitin-proteasome system. Target bicarbonate is typically 22-26 mmol/L. This is a nephrologist-prescribed therapy, not a self-managed supplement at the pharmacy.
Is follistatin a treatment option for CKD muscle wasting?
Not in any approved form. Some patients pursue commercial follistatin peptides hoping to counteract dialysis-related wasting, but no clinical trial supports that use, and the safety implications of layering follistatin on top of an already-immunocompromised dialysis patient are unstudied. Discuss any peptide use with the nephrology team before starting.
This article is for educational purposes only and is not medical advice. Chronic kidney disease and dialysis are serious conditions that require management by board-certified nephrologists, dialysis nurses, and renal dietitians. Exercise, protein intake, and any consideration of myostatin-targeted therapy in this setting must be coordinated with the patient's nephrology team. Do not change medications, diet, or activity based on online information alone.
